CureSearch Young Investigator Awards in Pediatric Oncology Drug Development

Sponsor Deadline: 

Oct 11, 2022

Letter of Intent Deadline: 

Aug 29, 2022


CureSearch for Children's Cancer

UI Contact: 

ProposalCentral link

CureSearch for Children’s Cancer supports the recruitment of promising early career scientists to a research career in pediatric oncology. Early career investigators are the most vulnerable to the shortfalls in federal research funding. The CureSearch Young Investigator program helps early career scientists begin their research programs and provides a pathway to independence. Since 2012, CureSearch has invested over $4.5M in Young Investigator awards to 27 grantees in research areas with high-risk and poor outcomes for children and adolescents and young adults with cancer: relapsed and high-risk ALL, AML, brain tumors, Ewing sarcoma, hepatoblastoma, neuroblastoma, lymphoma, rhabdiod tumors, rhabdomyosarcoma, malignant peripheral nerve sheath tumor, head and neck cancer, germ cell tumor, and Wilms tumor.

CureSearch’s mission is to drive innovative research to clinical impact to accelerate the delivery of novel therapeutics to pediatric cancer patients. A key component of this mission is to ultimately drive outstanding translational and preclinical research to clinical trials and beyond, towards commercialization. The 2022 Young Investigator Program is designed to provide support and training for exceptional young investigators in pediatric oncology drug development. The award is intended for investigators who have completed post-doctoral training and are transitioning to a full-time academic position. Up to five awards are available, contingent on the availability of funds, and will be based on the merits of the research proposed, the applicant’s previous productivity, ongoing mentorship during the transition, and the research environment. The applicant will receive $75,000 per year for three years (including a 10% indirect cost). Continued support for second- and third-year funding is contingent upon a noncompetitive review and demonstration of satisfactory and timely completion of milestones.